Cytokinetics

Forecast & Rating22 analysts currently cover Cytokinetics, with about 90.9% giving a positive rating — meaning they expect the stock to rise. The average price target is $107.80, about 31.6% upside from the current price of $81.92. Price targets range from $83.00 to $146.00 — a wide spread, showing clear disagreement over just how much Cytokinetics can rise. Historically, about 62.6% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Cytokinetics closely still see room for the stock to rise. Data as of Jul 22, 2026; for reference only and not investment advice.